Voacamine – 500 µg

Brand:
Cayman
CAS:
3371-85-5
Storage:
-20
UN-No:
Non-Hazardous - /

Voacamine is an alkaloid originally isolated from Voacanga that has diverse biological activities.{37654} It is a cannabinoid receptor 1 (CB1) antagonist (IC50 = 41 nM).{37655} Voacamine (1-10 µg/ml) time- and dose-dependently decreases survival of U2OS and multi-drug resistant U2OS (U2OS/DX) osteosarcoma cells and induces autophagy but not apoptosis.{37656} It also has antimalarial activity, inhibiting growth of P. falciparum in vitro at the trophozoite and schizont stages and reducing parasitemia in mice infected with P. yoelii when administered at doses of 2.5, 5, and 10 mg/kg.{37657}  

 

Available on backorder

SKU: 25204 - 500 µg Category:

Description

An alkaloid with diverse biological activities; a CB1 receptor antagonist (IC50 = 41 nM); time- and dose-dependently decreases survival of U2OS and U2OS/DX osteosarcoma cells and induces autophagy, but not apoptosis, at 1-10 µg/ml; inhibits growth of P. falciparum in vitro and reduces parasitemia in mice infected with P. yoelii when administered at doses of 2.5, 5, and 10 mg/kg


Formal name: 12-methoxy-13-[(3α)-17-methoxy-17-oxovobasan-3-yl]-ibogamine-18-carboxylic acid, methyl ester

Synonyms:  NSC 82591

Molecular weight: 704.9

CAS: 3371-85-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antiparasitics|Antiprotozoals||Product Type|Biochemicals|Natural Products|Alkaloids||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Autophagy||Research Area|Cancer|Cell Death||Research Area|Cancer|Multidrug Resistance||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Parasitic Diseases|Malaria||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors